INBX
INBX clinical trials: Inhibrx Biosciences, Inc.
Every trial on ClinicalTrials.gov where Inhibrx Biosciences, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 6
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
INBX on the catalyst calendar · INBX registry changes
- Primary completion Jul 2033Sponsor estimatePhase 1/Phase 2NCT04198766Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid...Inhibrx Biosciences, Inc · Solid TumorRecruitingINBXLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2029Sponsor estimatePhase 2/Phase 3NCT06295731Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)Inhibrx Biosciences, Inc · Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingINBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 1NCT03715933Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including SarcomasInhibrx Biosciences, Inc · Ewing SarcomaRecruitingINBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2025ActualPhase 2NCT04950075Study of INBRX-109 in Conventional ChondrosarcomaInhibrx Biosciences, Inc · Conventional ChondrosarcomaActive, not recruitingINBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 3, 2024ActualPhase 1NCT03809624Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck CancerInhibrx Biosciences, Inc · Metastatic Solid TumorsTerminatedINBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 18, 2022ActualPhase 1NCT03815396Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin DeficiencyInhibrx Biosciences, Inc · Alpha-1 Antitrypsin DeficiencyCompletedINBXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 2NCT06353997Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC PatientsProvidence Health & Services · Triple Negative Breast CancerRecruitingINBXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner